chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient received one dose of 0.2 adult pfizer by accident at 11 AM. Person who administered did not notice until she was documenting vaccine. Individual informed me what had happened. I called parents at 11:43 PM to see how patient was doing. First, I spoke to mother who states patient was acting like his normal self.  About 1 hour later I received call from father who was concerned. Explained to him what had happened. Father also informed me patient was well. Explained to him that since his it is his first vaccine the most important thing to monitor is for and acute allergic reaction to vaccine.  Father states patient did not have SOB, hives, angioedema or other symptoms. Informed dad that if he noticed any new symptoms arise to bring patient back into clinic. Father understood and had no additional questions or concerns.
Burning in left arm immediately after injection on 1/25/23 Burning chest pain on 1/26/23 Fever 101-102F on 1/27/23 Bilateral calf pain on 1/30/23 All spontaneously resolved
Achiness (that evening lasting 24 hours) Feeling hot and cold (varying for 36 hours) Headache (lasting 36 hours) Congestion (lasting 36 hours) Fatigue (lasting 36 hours) Soreness at injection site Red circle around injection site (lasting 3 days)
Felt nauseated first, vomiting started, eye swelling, red eyes, sweating - worsened as night progressed, went to ED around 11pm because of vomiting and shortness of breath.
37 year old female. No history or alopecia prior to 9/4/07. Past receipt of childhood Tdap and adult TD w/o problems.  First dose AVA given to right arm.  Had nodule for 2 weeks.  3rd days after vaccination noted hair pulling out while in shower and periodically thru out the day.  Then over next 5 days was severe with multiple strands of hair in brush and able to pull with hands w/o effort.  Over last 5 -6 weeks hair loss has slowed but still occurs. Has noted frontal hair thinning but no bald spots.  Reported episode to immunizations who referred to HC for evaluation.  Denied any joint pain, n/v/GI upset, rashes, headaches, myalgia, or any other concerns except site nodule.  Has not received further AVA vaccines since.
Patient with history of COVID vaccination admitted to hospital with COVID detected PCR. Provider discharge note, "Patient is a 53 YO male who presented to the hospital with unstable angina. Cardiac work-up revealed severe 3 vessel CAD with EF of 25%. The patent has had known ischemic cardiomyopathy and had a AICD placed a few years ago. The patient did develop fevers and leukocytosis shortly after admission and was found to be COVID-19 positive. Cardiac intervention was delayed to allow him to recover from active COVID infection. After appropriate isolation and stabilization from NSTEMI, the patient was recommended for cardiac surgery. He was brought to the operating room on 10/16/2023 and underwent CABG x 4 ( radial artery harvest). The patient tolerated the surgery well. He was monitored in the ICU and PCU setting. Postoperative course was uneventful. The patient was discharged home with family in stable condition on postoperative day 8. Please see daily progress notes for further details."
Dx-Cellulitis to right upper thigh. Sx-Right thigh very hot to touch, 8cm x 8cm area of induration around vaccine sites, does not appear to be painful to touch, has dark skin, indurated area is darkened in coloration. Tx-Start Cephalexin Suspension Reconstituted, 250 MG/5ML, 10 ml, Orally, twice a day, 10 day(s), BENADRYL for itching, and cool compresses for comfort.
Severe allergic reaction at injection site. Very large, inflamed/ puffy with lots of redness and itchiness.
Chills, bad headace, possible light fever from bedtime throughout the night (Friday night). Next day headace and tiredness all day (Sat). Felt fine by Sunday
Mult. 2 mm papules and 1-2 pustules noted on trunk and extremities and buttocks. Complained of itch, PT "felt fine." Scabbed over w/in 4-5 days.
Mondays night noticed a red/pink knot at site of injection. No itching, a little sore, no fever. Did not take anything or put anything on.
See attached clinical summary. (from summary:) "Flu-like symptoms; feeling tired all the time felt somewhat ill afterwards, but it did not seem to last to long".
Numbness and tingling to entire left extremity, migrated mid-line down to left side of rib cage. Also migrated to left side of neck and face, resulting in left side facial drooping with tongue thickening. No respiratory involvement.
Fever,chills,body aches, weakness, headache started 9 hours after the vaccination, lasted 36 hours.
Headache; body ache; temperature elevation from 100.4-101.8F till 102 degrees Fahrenheit; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 21-Apr-2021 and was forwarded to Moderna on 21-Apr-2021.    This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (Headache), MYALGIA (body ache) and PYREXIA (temperature elevation from 100.4-101.8F till 102 degrees Fahrenheit) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 040A21A and 040A21A) for COVID-19 vaccination.    Co-suspect product included non-company product NAPROXEN SODIUM (ALEVE) for an unknown indication.    No medical history was provided by the reporter.  Concomitant products included OMEPRAZOLE, ATORVASTATIN and HYDROCHLOROTHIAZIDE, VALSARTAN (VALSARTAN-HYDROCHLOROTHIAZIDE) for an unknown indication.   On 23-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started NAPROXEN SODIUM (ALEVE) (unknown route) at an unspecified dose. On 21-Apr-2021, the patient experienced HEADACHE (Headache), MYALGIA (body ache) and PYREXIA (temperature elevation from 100.4-101.8F till 102 degrees Fahrenheit). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, HEADACHE (Headache), MYALGIA (body ache) and PYREXIA (temperature elevation from 100.4-101.8F till 102 degrees Fahrenheit) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 21-Apr-2021, Body temperature increased: 100.4-101.8f till 102 100.4-101.8F till 102.         Treatment drugs included Tylenol and Aleve.   Reporter did not allow further contact
Pt onset 9/19 with vomiting and shortness of breath. Wife called 911 and Pt was transported late afternoon to Hospital. Plasma infusion on 9/20. Patient is fully vaccinated.
Information has been received from a physician concerning an 28 year old female patient who on 14-FEB-2010 was vaccinated with a first dose of GARDASIL (Lot # not provided). Concomitant therapy included a dose of HAVRIX and a dose of diphtheria toxoid and pertussis acellular vaccine (unspecified) and tetanus toxoid (manufacturer unknown).  It was reported that the patient developed a rash after receiving GARDASIL. On an unspecified date the patient had recovered. It was unknown if the patient sought medical attention. Additional information has been requested.
Less than 30 minutes after receiving vax, pt experienced symptoms of slow speech, head felt like it was jerking, arms felt heavy. By 7 PM (4 hrs), pt had fully recovered and was symptom free.
Head Ache. Severe Tiredness, Weakness, Pain Redness Swelling and Itching in arm for several days. Arm is still sore and red today, Monday May 9th.
Patient reported that about 3 hours following the vaccine, she started to feel nauseous while driving home. She had nausea and vomiting and when I talked to her she was in the ER to see if they could determine the cause or help with her symptoms. She said she felt very cold and shaky.
Since second shot on Mat 4th I have had headaches 2 to 3 times a week not migraine level but pretty intense.
no additional adverse effect reported; "patient received MMR II in one injection site on 27-MAY-2020 and PROQUAD in another injection site on 27-MAY-2020."; This spontaneous report was received from the office manager, referring to a 12-month-old patient. The patient's pertinent medical history, concurrent conditions, previous drug reactions or allergies, and concomitant medications were not reported.  On 27-MAY-2020, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (rHa)(M-M-R II) injection as prophylaxis in one site (dosage regimen and anatomical location were not reported; lot number S014429, which has been verified to be valid, expiration date reported and validated as 09-MAY-2021), and measles, mumps, rubella and varicella (oka-merck) virus vaccine live (rHa)(PROQUAD) injection as prophylaxis in another site (dosage regimen and anatomical location were not reported; lot number S017240, which has been verified to be valid, expiration date reported and validated as 01-DEC-2020) (inappropriate schedule of product administration). Sterile diluent (MERCK STERILE DILUENT) was used. No additional adverse effect reported.
On 7/8/09 patient received following vaccinations:  L leg - IPV and Varicella.   R leg - MMR and DTaP.  Grandma reported that the evening after vaccination patient began having localize swelling.  I saw patient in clinic on 7/10/09 for large localized swelling at the vaccine sites.  On L leg at vaccine injection sites, he had a 10x14cm region of erythema and swelling with some induration, slightly pale skin circumferentially but not tender to touch.  On R leg he had a 3x4cm of swelling at one vaccine site, small red macule at other vaccine site.
Patient given 1.0 mL of vaccine instead of 0.5 mL. Error identified within 5 minutes. Patient observed for 15 minutes, had no adverse reactions. Patient informed of error, advised to seek medical care if he has any severe side effects.
Noted swollen lymph glands in neck the same evening as vaccine given Right side of neck and vaccine given on right arm (shoulder) Right deltoid.
Patient left clinic with mother and sister after they all got vaccines. Patient began to get nauseous, turned pale, vomited phlegm. Provider had the patient lay down in clinic, mother brought her a lemonade. She drank the lemonade and continued to lay down. Within minutes she got her color back and felt better.
Difficulty breathing within 10 minutes for DT, MMR, IPV; rash on trunk itchy-cough vomited x 1 lungs clear. Administered 1 1/4-1 1/2 tsp Benadryl and observation x 1 1/2 pt active and alert.
I developed what I call skipped beat feeling in my heart or ireegular beats. Dr confirmed with halter monitor there were premature atrial contractions(PAC) and premature ventricular contractions. (PVC)
Overall cognitive decline, brain fog, headaches, fatigue. Most concerning is the brain fog. Am not able to work as much as prior to the vaccine. I am worried about cognitive impairment getting worse. I was super mentally sharp and that shot has eliminated my mental sharpness.
runny nose; coughing; muscle aches; dizziness; This is a spontaneous report from a contactable consumer (patient) reported for himself. A male patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 Vaccine,), dose 1 via an unspecified route of administration on 08Apr2021 as a single dose Batch/Lot number was not reported for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. On 08Apr2021, the patient had adverse reactions, including runny nose, coughing, muscle aches, dizziness and lasted until 10Apr2021. The outcome of events was unknown.   The  Centers for Disease Control & Prevention (CDC)'s Advisory Committee on Immunization Practices (ACIP) has provided interim considerations for the use of mRNA COVID-19 Vaccines during the Emergency Use Authorization. These interim considerations state mRNA vaccines, including the Pfizer BioNTech COVID-19 vaccine, can safely be given to persons with a history of a prior COVID-19 infection. The vaccine should be offered even if you had symptoms or no symptoms of COVID-19 infection.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Vaccine that administered beyond use date after the thaw process/expired vaccine administered; This spontaneous case was reported by a paramedic and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine that administered beyond use date after the thaw process/expired vaccine administered) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027H21B) for COVID-19 prophylaxis.     It was unknown if patient had chronic or long lasting health conditions.     On 27-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .25 milliliter. On 27-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine that administered beyond use date after the thaw process/expired vaccine administered). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine that administered beyond use date after the thaw process/expired vaccine administered) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.  Patient age was reported as 35 years 11 months.   It was reported that  patient had no adverse reactions and no reports of adverse reactions after the administration of the vaccine.  It was unknown if patient had acute illness at the time of vaccination and up to one month before.  It was unknown if patient had been diagnosed with or tested positive for COVID-19.  No treatment medications were reported.
After administering a vaccine, patient reported flushing; a little scratchy throat; post nasal drip;
6 YO was administered Bexsero; This case was reported by a physician via call center representative and described the occurrence of inappropriate age at vaccine administration in a 6-year-old male patient who received Men B NVS (Bexsero) (batch number A2X3Y, expiry date 28th February 2023) for prophylaxis.   Co-suspect products included meningococcal B recom vaccine + aloh + omv pre-filled syringe device (Bexsero Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 2nd November 2022, the patient received Bexsero and Bexsero Pre-Filled Syringe Device. On 2nd November 2022, unknown after receiving Bexsero and Bexsero Pre-Filled Syringe Device, the patient experienced inappropriate age at vaccine administration. On an unknown date, the outcome of the inappropriate age at vaccine administration was unknown.     This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK receipt date: 2-Nov-2022 Reporter's comment: The medical physician called to inquired any precautions, any advice on what to do on their end. The reporter confirmed that the vaccine was administered in their facility just a couple of hours ago. The reporter did not consent to follow-up. Additional supportive information: The patient was accidentally administered Bexsero in left deltoid at inappropriate age, which led to inappropriate age at vaccine administration.
Pt states that she is fully vaccinated for COIVID. Admitted with nausea and vomiting. Tested Positive for COVID upon admission
Pt given Pneumovax in (L) arm 10/01/19. Within hours severe pain and very significant swelling. 5 hours later felt nauseated. Went to ER and was given Prednisone and diphenhydramine. Sent with the same Rx's to take for 4 days.
Repeated hypoglycemic episodes beginning sitting in 30 minutes of shot continuing off and on for seven days.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 47 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 09Jul2021 17:30 (Lot number: ER8729) at the age of 47 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Hypoglycaemia" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Erythromycin, reaction(s): "Known allergies: Erythromycin". The following information was reported: HYPOGLYCAEMIA (non-serious) with onset 09Jul2021 18:00, outcome "recovering", described as "Repeated hypoglycemic episodes beginning sitting in 30 minutes of shot continuing off and on for seven days.". Therapeutic measures were not taken as a result of hypoglycaemia.  Additional information: The patient did not received any other vaccine in four week and received Asea redox medication in two weeks. The patient doesn't have Covid prior to the vaccination and doesn't tested for Covid post vaccination. Facility where vaccine was administered Doctor's office/urgent care.  No follow-up attempts are possible. No further information is expected.
I have shortness of breath and rapid heart beating, chest pain under left breast.  My blood pressure is sky high and I have NEVER had high blood pressure 160/101. I have been monitoring my pressure daily and it is not going down!! I NEVER smoked and did NOT have these problems prior to vaccine.
sore throat; cough; cold type symptoms; This is a spontaneous report from a Pfizer sponsored program. A contactable physician reported for a patient that: A male patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: was not reported), via an unspecified route of administration, administered on Jan2021as dose 2, single for COVID-19 immunization. The patient medical history was not reported. The patient's concomitant medications were not reported. Patient previously received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection; Expiry Date: unknown, Lot number: unknown), via an unspecified route of administration on unspecified date in Dec2020as dose1, single for COVID-19 immunization. Reporter states he as a patient that received his first dose of the Pfizer COVID-19 vaccine in Dec2020 and the second dose of the Pfizer COVID-19 vaccine in Jan2021. Patient has been tested for the spike antibodies and he has them and is fully protected. Reporter states his patient has been extremely careful with wear the mask and gloves but the patients now has symptoms that started on Tuesday of sore throat, cough, no fever and Oxygen saturation has been 99-100%. Caller would like to know if this could be a breakthrough COVID-19 case. Reporters doctor friend (patient) did the labs and it does show immunity to the virus but now he has cold type symptoms and his friend is "freaking" out that he may have the variant and he was asking if this was what was going on. The patient underwent lab tests and procedures which included spike antibody test: fully protected on an unspecified date in 2021, oxygen saturation: 99-100 % on an unspecified date in 2021. The outcome of event was recovering.    Information about batch/ lot number has been requested.
Pfizer COVID Vaccine EUA: COVID-19 case resulting in Hospitalization / Death. Patient received Pfizer Vaccine on 1/15/21, 3/04/21, and 3/25/21. Covid + 1/18/22. Presented to ED 1/27 w/symptoms x9 days related to COVID-19 infection. In ED, vitals showed T 99.4F, BP 104/70 mmHg, satting 99% on RA. Metabolic acidosis (venous pH 7.29), elevated Cr of 1.96, Na 133. Morning of 01/31, acutely desatted to mid 80s and developed mild tachypnea, later fevered to 102.2F placed on CPAP. Continued to deteriorate, transitioned to DNAR. Tx'd with cefepine remdesivir, dexamethasone and vancomycin. Pt expired on 2/11/2022.
Hard lump and redness at injection site on right deltoid almost immediately after injection. Patient describes a "fireball" in her throat. Denies swelling. No difficulty swallowing, maintaining airway independently. Headache.  In E.D., patient received NS 1000 ml at 2000 ml/hr at 19:34, Diphenhydramine 25 mg IV x1 at 19:36, Methylprednisolone 125 mg IV at 19:38, Ketorolac 30 mg IV at 19:41, Famotidine 20 mg IV at 19:42.  Forty minutes post injection, all symptoms gone. Discharged from E.D. at 20:52 with prescription for prednisone 50 mg po daily x4 days, diphenhydramine 25 mg po q6h prn, and famotidine 20 mg po nightly prn.
Information has been received from a physician concerning a 9 year old female who was vaccinated with a dose of varicella virus vaccine live. Subsequently, the patient developed varicella wild type breakthrough. Her case was considered to be serious (OMIC). It was reported that the patient transmitted the varicella infections to an uncle (WAES0406USA01126) who had never been immunized or had never developed wild type varicella in the past. The uncle was subsequently vaccinated with Varivax and still developed the wild type infection. Unspecified medical attention was sought. There was no product quality complaint involved. Upon internal review, the patient's varicella breakthrough was considered to be an other important medical event (OMIC). The patient's brother (WAES0406USA01125) also developed an adverse event after vaccination with varicella virus vaccine live. Additional information has been requested.
rash devel over body on 8OCT92, same day as vax treated on 11OCT92 by pvt MD; rash lasted approx 10 days;
6/7 76 yo M with hx of HTN presents to the EC with complaints of R chest wall and bilateral flank pain x 1 week.
Rash all over body. Swollen lymph node. Morbilliform rash. No treatment needed.
chills, fever 100.7 - 24 hours achiness, extreme weakness -  4 days
On 11/7/00, pt was given his MMR vaccine and 9 days later, he developed high fevers for 2 days. On 11/16/00, he started to develop a rash that was measles-like. The rash started to disappear on 11/19/2000. Treated with Augmentin.
Pt developed fever and "spots in throat" 5d post vaccine followed by slight rash that then turned into classic measles rash 12/28/03.
Had excessive nosebleed within 24 hours after the shot. Had 2 additional nosebleeds within following 3 weeks.
12 hours after second vaccine she developed fever, vomiting, diarrhea, and lightheadedness. Symptoms lasted 24 hours.
Patient did not experience any adverse reactions and did not require any treatment relating to the event. The time elapsed between the first and second dose is 8 weeks and 5 days, however the time interval between the second and third injections is 9 weeks and 6 days and the interval between the first and third injections is 18 weeks and 4 days; this timeframe is less that the minimum required for this series of injections. The patient has not experienced any adverse effects related to the early administration of the third and final of the GARDASIL vaccine. There has been clear re-education with clinical staff as to the required immunization schedule and the importance of strictly adhering to it, as well as following the correct administration protocol. The CDC was contacted to confirm the patient's need for an additional GARDASIL immunization as the third injection was prior to the minimum interval. The patient patent was contacted, made aware of the situation, and informed that he would need an appointment so that the vaccine could be administered. He indicated he would discuss it with his mother and he would call back to schedule that appointment. If you have any questions regarding this situation please contact our office.
pt recv vax 28OCT98 130PM & arm was not too sore p/shot;woke up & both hands were swollen from fingertips to wrists which lasted 630AM-1030AM;c/o very bad h/a;c/o 30OCT throat feeling funny congested "swollen";felt like gland swollen;